analytical variation; bone specific alkaline phosphatase; dialysis patients; standardization
Abstract :
[en] BACKGROUND:
Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods available to measure BAP.
METHODS:
We measured BAP in 76 HD patients with six different assays (Beckman-Coulter Ostase IRMA, Beckman-Coulter Ostase Access, IDS iSYS Ostase, IDS Ostase enzyme immunoassay, DiaSorin Liaison Ostase and Quidel MicroVue BAP).
RESULTS:
We observed a high correlation between all the assays ranging from 0.9948 (IDS iSYS vs. IDS EIA) to 0.9215 (DiaSorin Liaison vs. Quidel MicroVue). However, using the regression equations, the equivalent concentration of a Beckman-Coulter Access value of 10μg/L can range from 7.7 to 14.4μg/L and of 20μg/L can range from 16.9 to 27.9μg/L with other assays. According to Beckman-Coulter Access, 13%, 50% and 37% of the patients presented BAP values ≤10, between 10 and 20 and ≥20μg/L, respectively. Discrepancies are observed when other assays are used (concordance from 10 to 100%).
CONCLUSIONS:
Analytical problems leading to inter-method variation should be overcome to improve the usefulness of this marker in clinical practice. According to correlation results, recalibration of BAP assays is necessary but should not be a major issue.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Souberbielle, Jean-Claude
GADISSEUR, Romy ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
DUBOIS, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Delanaye P., Souberbielle J.C., Lafage-Proust M.H., Jean G., Cavalier E. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 2014, 29(5):997-1004.
Sardiwal S., Magnusson P., Goldsmith D.J., Lamb E.J. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis 2013, 62:810-822.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD work group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009, 6:S1-S130.
Souberbielle J.C., Boutten A., Carlier M.C., Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006, 70:345-350.
Couttenye M.M., D'Haese P.C., Verschoren W.J., Behets G.J., Schrooten I., De Broe M.E. Low bone turnover in patients with renal failure. Kidney Int Suppl 1999, 73:S70-S76.
Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7:506-512.
Cavalier E., Delanaye P., Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013, 61:847-848.
Sardiwal S., Gardham C., Coleman A.E., Stevens P.E., Delaney M.P., Lamb E.J. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012, 82:100-105.
FDA 510(k) clearance of the Beckman-Coulter Access Ostase (Reference K994278) 2000, [13-11-2013.Ref Type: Internet Communication].
Teco Medical Bone alkaline phosphatase (BAP): a biochemical marker of bone turnover 2013, [13-11-2013.Ref Type: Internet Communication].
FDA Class 2 Recall Access Ostase 2012, [13-11-2013.Ref Type: Internet Communication].